Blue light induces ROS mediated apoptosis and degradation of AML1-ETO oncoprotein in Kasumi-1 cells

被引：0
作者：
Jianjian Zhuang
Liping Xia
Zheyu Zou
Juxin Yin
机构：
[1] Zhejiang University City College,School of Information and Electrical Engineering
[2] Zhejiang University School of Medicine,Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Cancer Center
[3] Zhejiang University,College of Life Sciences
来源：
Medical Oncology | 2022年 / 39卷
关键词：
Cell viability; Apoptosis; Kasumi-1; Caspase-3; AML1-ETO;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Light-emitting diode (LED)-based therapies, particularly blue LEDs with wavelengths of 400–500 nm, have shown beneficial results in several cancers, including melanoma, lymphoid cells, and skin tumors. In this study, the cell viability and apoptosis of Kasumi-1 cells treated by blue light (BL) irradiation have been explored. Firstly, BL can specially inhibit the proliferation and promote the apoptosis of Kasumi-1 cells. Furthermore, the apoptosis was triggered by the production of reactive oxygen species and the decline of mitochondrial membrane potential which was regulated by the ratio of Bcl-2(Bcl-xL)/Bax; BL caused the cells’ final apoptosis accompanied with the increased cleavage of caspase-3 and poly-ADP-ribose polymerase. Finally, BL induced the degradation of AML1-ETO dependent on the activation of caspase-3. These results are helpful for establishing a low toxicity and high efficiency strategy of BL irradiation for clinical treatment of Kasumi-1 cells.
引用
收藏
相关论文
共 163 条
[1]  
Galal SA(2017)Part I: Design, synthesis and biological evaluation of novel pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors with studying their activities alone and in combination with genotoxic drugs Eur J Med Chem 134 392-405
[2]  
Abdelsamie AS(1995)t(8;21) myelodysplasia, an early presentation of M2 AML Brit J Haematol 89 890-892
[3]  
Shouman SA(2004)The 8;21 translocation in leukemogenesis Oncogene 23 4255-1886
[4]  
Attia YM(2012)Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia Ann Hematol 91 1879-1062
[5]  
Ali HI(1999)Acute myeloid leukemia N Engl J Med 341 1051-1674
[6]  
Tabll A(1991)Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 77 1666-1111
[7]  
El-Shenawy R(1992)A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study J Clin Oncol 10 1103-75
[8]  
El Abd YS(1992)Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 79 313-319
[9]  
Ali MM(2006)Combination blue (415 nm) and red (633 nm) LED phototherapy in the treatment of mild to severe acne vulgaris J Cosmet Laser Ther 8 71-411
[10]  
Mahmoud AE(2006)Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease Eur J Pediatr 165 306-38901
12345678910